Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Chemoproteomic identification and therapeutic validation of proteins of metabolic significance Resource Report Resource Website |
Chemoproteomic identification and therapeutic validation of proteins of metabolic significance (RRID:SCR_015847) | project portal, data or information resource, database, portal | Database portal for a project that aims to discover and characterize new molecular pathways that can be targeted pharmacologically to revert obesity-linked adipocyte defects that drive systemic insulin resistance and type 2 diabetes. It works to identify in tandem physiologically-relevant proteins and chemical tools in order to expedite their functional annotation and therapeutic validation. | diabetes, type II diabetes, compound, genetic model, metabolic disease, molecular pathway, obesity, adipocyte, insulin resistance | has parent organization: Scripps Research Institute | obesity, Diabetes, Type II Diabetes | NIDDK DK099810; NIDDK DK114785 |
Freely available, Public | SCR_015847 | 2026-02-15 09:21:39 | 0 | ||||||||
|
Monogenic Diabetes Registry Resource Report Resource Website |
Monogenic Diabetes Registry (RRID:SCR_015883) | MDR, NDR, MODYR | project portal, data or information resource, database, portal | Research project that aims to learn more about the number of people who have monogenic diabetes, why and how it happens, and how best to treat it. Any adult or child with a known genetic cause of diabetes may join the MODY Registry. | monogenic, diabetes, neonatal, mody, diabetes research, genetic disease |
is listed by: NIDDK Information Network (dkNET) is listed by: Diabetes Research Centers has parent organization: University of Chicago; Illinois; USA |
Diabetes, Monogenic Diabetes, Neonatal Diabetes, MODY | NIDDK | Public, Diagnosed individuals may register, Freely available | SCR_015883 | MODY Registry, Neonatal Diabetes Registry | 2026-02-15 09:21:26 | 0 | ||||||
|
National Glycohemoglobin Standardization Program Resource Report Resource Website 500+ mentions |
National Glycohemoglobin Standardization Program (RRID:SCR_015885) | NGSP | project portal, data or information resource, portal | Project that aims to standardize Hemoglobin A1c test results to those of the Diabetes Control and Complications Trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS) which established the direct relationships between HbA1c levels and outcome risks in patients with diabetes. | glycohemoglobin, diabetes, dcct, ukpds, hba1c, diabetes patient, hemoglobin, a1c |
is listed by: NIDDK Information Network (dkNET) is listed by: Diabetes Research Centers |
Diabetes | NIDDK UC4 DK096587 | Public | SCR_015885 | NGSP: National Glycohemoglobin Standardization Program | 2026-02-15 09:20:59 | 922 | ||||||
|
La Jolla Institute for Immunology Resource Report Resource Website |
La Jolla Institute for Immunology (RRID:SCR_014837) | LJI, | organization portal, data or information resource, portal | Non profit collaborative research organization located in La Jolla, California, UCSD Research Park. Institute researches immunology and immune system diseases to pinpoint specific genes involved, accelerate progress toward development of new treatments and vaccines to prevent and cure type 1 diabetes, cancer and infectious disease. Developer of Immune Epitope Database (IEDB). Provides core facilities with access to equipment, technologies, training and expertise to support innovative research. | Immunology, vaccine, infectious disease, immune system, Immune Epitope Database, sequencing, high throughput, bioinformatics |
is related to: Coronavirus Immunotherapy Consortium is parent organization of: Database of Immune Cell Epigenomes is parent organization of: La Jolla Institute for Immunology Next Generation Sequencing Core Facility |
Type 1 diabetes, Diabetes, Allergy, Alzheimer's disease, Asthma, Atherosclerosis, Atopic dermatitis, Eczema, Autoimmune disease, Cancer, COVID-19, Dengue, Ebola, Fibrosis, Food allergies, HIV, Imflammatory bowel disease, Japanese encephalitis, Lassa fever, Lung cancer, Multiple sclerosis, Nipah, Parkinson's disease, Pneumonia | SCR_014837 | LJI, la jolla, Institute for immunology, La Jolla Institute for Allergy and Immunology | 2026-02-15 09:21:04 | 0 | ||||||||
|
Rare and Atypical Diabetes Network Resource Report Resource Website 1+ mentions |
Rare and Atypical Diabetes Network (RRID:SCR_024732) | RADIANT | portal, database, data or information resource, topical portal, disease-related portal | Portal dedicated to characterizing, discovering and defining rare and atypical forms of diabetes. Network of universities, hospitals and clinics across the United States dedicated to better understanding atypical diabetes. Team of academic institutions and scientists collaborates with physicians and healthcare groups to identify those with atypical diabetes and learn more about their health. | USA, universities network, hospitals and clinics network, characterizing atypical diabetes, discovering atypical diabetes, defining atypical diabetes, rare and atypical forms of diabetes, atypical diabetes, |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Central Repository |
rare and atypical forms of diabetes, Diabetes | NIDDK | Restricted | SCR_024732 | Rare and Atypical DIAbetes NeTwork | 2026-02-15 09:22:47 | 2 | ||||||
|
Merck Resource Report Resource Website 10000+ mentions |
Merck (RRID:SCR_001287) | Merck | commercial organization | An American pharmaceutical company aiming to make a difference in the lives of people globally through their medicines, vaccines, biologic therapies and animal health products. | pharmaceutical, merck sharp & dohme corp, merck sharp and dohme corp, merck sharp and dohme, merck sharp & dohme corp., msd, medicine, endocrinology, neuroscience, oncology, respiratory, immunology, vaccine, animal health, veterinary |
uses: Kaggle uses: Tableau Desktop uses: FluoroFinder is affiliated with: European Federation of Pharmaceutical Industries and Associations is related to: eTRIKS is related to: OncoTrack is related to: European Lead Factory is related to: GetReal is related to: Investigator Databank is related to: Kinetics for Drug Discovery is related to: MIP-DILI is related to: ORBITO is related to: PharmaCog is related to: Asian Cancer Research Group is related to: Open PHACTS is related to: Collaboratory of AIDS Researchers for Eradciation (CARE) is parent organization of: MEDINA Foundation is parent organization of: Asian Cancer Research Group is parent organization of: Asia Training Consortium |
Diabetes, Cancer, Cardiovascular disease, Infectious disease | Crossref funder ID: 100004334, grid.417993.1, Wikidata: Q247489, ISNI: 0000 0001 2260 0793, nlx_152409 | https://ror.org/02891sr49 | SCR_001287 | Merck and Co., Merck and Co. Inc., Merck & Co. Inc., Merck & Co. | 2026-02-14 01:59:57 | 10277 | ||||||
|
Foundation for the National Institutes of Health Resource Report Resource Website 1000+ mentions |
Foundation for the National Institutes of Health (RRID:SCR_004493) | FNIH | institution | A public charity whose mission is to support the NIH in its mission to improve health, by forming and facilitating public-private partnerships for biomedical research and training. Its vision is Building Partnerships for Discovery and Innovation to Improve Health. The FNIH draws together the world''s foremost researchers and resources, pressing the frontier to advance critical discoveries. They are recognized as the number-one medical research charity in the countryleveraging support, and convening high level partnerships, for the greatest impact on the most urgent medical challenges we face today. Grants are awarded as part of a public-private partnership with the National Heart, Lung, and Blood Institute (NHLBI) on behalf of The Heart Truth in support of women''s heart health education and research. Funding for the Community Action Program is provided by the FNIH through donations from individuals and corporations including The Heart Truth partners Belk Department Stores, Diet Coke, and Swarovski. Successful biomedical research relies upon the knowledge, training and dedication of those who conduct it. Bringing multiple disciplines to bear on health challenges requires innovation and collaboration on the part of scientists. Foundation for NIH partnerships operate in a variety of ways and formats to recruit, train, empower and retain their next generation of researchers. From lectures and multi-week courses, to scholarships and awards through fellowships and residential training programs, their programs respond to the needs of scientists at every level and stage in their careers. | biomedical research |
is related to: Osteoarthritis Biomarkers Project (OABP) is parent organization of: Biomarkers Consortium is parent organization of: Observational Medical Outcomes Partnership is parent organization of: Accelerating Medicines Partnership Autoimmune Diseases of Rheumatoid Arthritis and Lupus is parent organization of: Accelerating Medicines Partnership - Alzheimers is parent organization of: Accelerating Medicines Partnership Type 2 Diabetes Knowledge Portal (AMP-T2D) is parent organization of: Genetic Association Information Network (GAIN) |
Type 1 diabetes, Type 2 diabetes, Diabetes, Metabolic disease, Alzheimer's disease, Schizophrenia, Prostate cancer, Demantia, Muscular dystrophy, Tuberculosis, HIV, Parkinson's disease, Osteoarthritis, Age-related eye disease, Visceral leishmaniasis, Undiagnosed disease, Cancer, Non-small cell lung cancer, Malaria, Systemic lupus erythematosus, COVID-19, Acute lymphoblastic leukemia | ISNI: 0000 0000 9836 9834, Wikidata: Q16837497, nlx_143768, Crossref funder ID: 100000009, grid.428807.1 | https://ror.org/00k86s890 | SCR_004493 | Foundation for NIH | 2026-02-14 02:00:44 | 1788 | ||||||
|
American Diabetes Association Resource Report Resource Website 1000+ mentions |
American Diabetes Association (RRID:SCR_004526) | ADA | non profit organization | The mission of the American Diabetes Association (ADA) is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. We lead the fight against the deadly consequences of diabetes and fight for those affectedby diabetes. * We fund research to prevent, cure and manage diabetes. * We deliver services to hundreds of communities. * We provide objective and credible information. * We give voice to those denied their rights because of diabetes. | diabetes, diabetes mellitus, type 1 diabetes, type 2 diabetes, gestational diabetes | Type 1 diabetes, Type 2 diabetes, Diabetes | Crossref funder ID: 100000041, ISNI: 0000 0001 1033 6008, Wikidata: Q4743610, nlx_143804, grid.427608.f | https://ror.org/04f6cgz95 | SCR_004526 | 2026-02-14 02:00:42 | 1256 | ||||||||
|
reMYND Resource Report Resource Website 1+ mentions |
reMYND (RRID:SCR_003824) | reMYND | commercial organization | Organization that drives the development of disease-modifying treatments against Alzheimer's, Parkinson's, Diabetes and other protein misfolding disorders through two independently managed business units: * Contract Research: The in-vivo Contract Research Organization (CRO) helps its clients to assess the pharmacokinetics and -dynamics of their experimental treatments against Alzheimer's disease. The main focus is on efficacy testing of candidate drugs in reMYND's proprietary Alzheimer mouse models expressing the clinical APP-London allele as single transgene or in combination with clinical alleles of human PS1 and TAU. * Drug Discovery: The Drug Discovery and Development Unit (DDD) focuses on disease-modifying treatments against protein-misfolding disorders, such as Alzheimer's disease (tau), Parkinson's disease (-synuclein), and Diabetes. In addition, reMYND grants licenses and markets commercial kits of RadarScreen, a technology for rapid and cost-effective identification of genotoxic liabilities in early stage drug discovery. reMYND has been substantially supported by grants from IWT and from The Michael J Fox Foundation. | protein misfolding | Alzheimer's disease, Parkinson's disease, Diabetes | IWT ; Michael J. Fox Foundation for Parkinson's Research |
nlx_158130 | SCR_003824 | reMYND NV | 2026-02-14 02:00:53 | 1 | |||||||
|
Diamyd Medical Resource Report Resource Website 1+ mentions |
Diamyd Medical (RRID:SCR_003930) | DMYD B | commercial organization | A diabetes company active in the field of pharmaceutical development. The Company develops the diabetes vaccine Diamyd with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd to global Phase III trials, leading to one of Sweden''s largest biotech agreements ever. The company has secured an exclusive license for a patent application for the specific combination therapy GAD plus the endogenous substance GABA, which has demonstrated favorable results in preclinical trials. The license also encompasses rights for the therapeutic use of GABA to treat diabetes and other inflammation-related disorders. | pharmaceutical, drug development, drug | is related to: Pharma-Planta Consortium | Type 1 diabetes, Diabetes | nlx_158298 | SCR_003930 | Diamyd Medical AB | 2026-02-14 02:00:33 | 2 | |||||||
|
Heptares Therapeutics Resource Report Resource Website |
Heptares Therapeutics (RRID:SCR_000499) | commercial organization | A drug discovery company focused on small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets. Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. They are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilization, structure determination, and fragment-based discovery. Their partners include Cubist, MorphoSys, AstraZeneca, MedImmune and Takeda. Their objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer's disease, schizophrenia, diabetes, ADHD and chronic migraine. | g-protein coupled receptor, small molecule, drug, biotechnology, medicine, antibody, drug discovery | is related to: Kinetics for Drug Discovery | Alzheimer's disease, Schizophrenia, Diabetes, Attention deficit-hyperactivity disorder, Chronic migraine | nlx_158498, grid.450873.d, ISNI: 0000 0004 0456 4700 | https://ror.org/051fk5x88 | SCR_000499 | Heptares Therapeutics Limited, Heptares Therapeutics Ltd, Heptares | 2026-02-14 01:59:44 | 0 | |||||||
|
Helmsley Charitable Trust Resource Report Resource Website |
Helmsley Charitable Trust (RRID:SCR_005111) | Helmsley Charitable Trust | funding resource | The Leona M. and Harry B. Helmsley Charitable Trust supports a broad spectrum of healthcare and medical research-based programs. The areas supported include Type 1 Diabetes, Digestive Diseases, Rural Healthcare, Cardiology, and a range of other programs and institutions. | grant, health, medical research, type 1 diabetes, digestive disease, rural healthcare, cardiology | is parent organization of: Helmsley Cellular Research Hub | Type 1 diabetes, Diabetes, Crohn's disease | nlx_144118 | SCR_005111 | Leona M. and Harry B. Helmsley Charitable Trust, Leona M. Harry B. Helmsley Charitable Trust | 2026-02-14 02:01:04 | 0 | |||||||
|
T1D Exchange Resource Report Resource Website 10+ mentions |
T1D Exchange (RRID:SCR_014532) | commercial organization | Provides access to resources T1D researchers need to conduct clinical studies. Data sets from their clinic registry is openly available, as are new study results. They also offer use of T1D Discovery Tool, which allows users to search different fields from registry data, and T1D Exchange Biobank, which offers specimen types such as serum, plasma, white blood cells, DNA, and RNA. | portal, dataset, type 1 diabetes, t1d, clinical, study, registry, data |
is listed by: NIDDK Information Network (dkNET) is related to: Type 1 Diabetes Knowledge Portal is parent organization of: T1D Exchange Biobank |
Type 1 diabetes, Diabetes | grid.461811.b | https://ror.org/016jvas21 | SCR_014532 | T1D Exchange Inc. | 2026-02-14 02:02:40 | 12 | |||||||
|
Accelerating Medicines Partnership Resource Report Resource Website 1+ mentions |
Accelerating Medicines Partnership (RRID:SCR_014927) | AMP | group | Partnership between the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and multiple biopharmaceutical companies and non-profit organizations whose goal is to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them. The group explores three major areas of disease: diabetes, Alzheimer's disease, and rheumatoid arthritis and lupus. | group, partnership, nih, fda, medicine, diabetes, alzheimers, alzheimer's, rheumatoid arthritis, lupus |
has parent organization: National Institutes of Health is parent organization of: Accelerating Medicines Partnership Autoimmune Diseases of Rheumatoid Arthritis and Lupus is parent organization of: Accelerating Medicines Partnership - Alzheimers is parent organization of: Accelerating Medicines Partnership Type 2 Diabetes Knowledge Portal (AMP-T2D) |
diabetes, Alzheimer's disease, rheumatoid arthritis, lupus | SCR_014927 | Accelerating Medicines Partnership (AMP) | 2026-02-14 02:02:46 | 3 | ||||||||
|
Sequencing of Idd regions in the NOD mouse genome Resource Report Resource Website 1+ mentions |
Sequencing of Idd regions in the NOD mouse genome (RRID:SCR_001483) | Sequencing of Idd regions in the NOD mouse genome | data or information resource, data set, resource | Genetic variations associated with type 1 diabetes identified by sequencing regions of the non-obese diabetic (NOD) mouse genome and comparing them with the same areas of a diabetes-resistant C57BL/6J reference mouse allowing identification of single nucleotide polymorphisms (SNPs) or other genomic variations putatively associated with diabetes in mice. Finished clones from the targeted insulin-dependent diabetes (Idd) candidate regions are displayed in the NOD clone sequence section of the website, where they can be downloaded either as individual clone sequences or larger contigs that make up the accession golden path (AGP). All sequences are publicly available via the International Nucleotide Sequence Database Collaboration. Two NOD mouse BAC libraries were constructed and the BAC ends sequenced. Clones from the DIL NOD BAC library constructed by RIKEN Genomic Sciences Centre (Japan) in conjunction with the Diabetes and Inflammation Laboratory (DIL) (University of Cambridge) from the NOD/MrkTac mouse strain are designated DIL. Clones from the CHORI-29 NOD BAC library constructed by Pieter de Jong (Children's Hospital, Oakland, California, USA) from the NOD/ShiLtJ mouse strain are designated CHORI-29. All NOD mouse BAC end-sequences have been submitted to the International Nucleotide Sequence Database Consortium (INSDC), deposited in the NCBI trace archive. They have generated a clone map from these two libraries by mapping the BAC end-sequences to the latest assembly of the C57BL/6J mouse reference genome sequence. These BAC end-sequence alignments can then be visualized in the Ensembl mouse genome browser where the alignments of both NOD BAC libraries can be accessed through the Distributed Annotation System (DAS). The Mouse Genomes Project has used the Illumina platform to sequence the entire NOD/ShiLtJ genome and this should help to position unaligned BAC end-sequences to novel non-reference regions of the NOD genome. Further information about the BAC end-sequences, such as their alignment, variation data and Ensembl gene coverage, can be obtained from the NOD mouse ftp site. | genome, sequencing, genome sequencing, insulin-dependent diabetes, c57bl/6j, single nucleotide polymorphism, genetic variation, bacterial artificial chromosome, sequence, gene, animal model, clone, annotation, contig |
lists: VEGA is listed by: NIDDK Information Network (dkNET) has parent organization: Wellcome Trust Sanger Institute; Hinxton; United Kingdom |
Type 1 diabetes, Diabetes | NIAID AI 15416; NIDDK ; JDRF |
PMID:23729657 | Free, Freely available | nlx_152738 | http://www.sanger.ac.uk/resources/mouse/nod/ | SCR_001483 | Sequencing of Insulin-dependent diabetes regions in the NOD mouse genome | 2026-02-14 02:05:20 | 1 | |||
|
Resource for Genetic Epidemiology Research on Adult Health and Aging Resource Report Resource Website 1+ mentions |
Resource for Genetic Epidemiology Research on Adult Health and Aging (RRID:SCR_010472) | GERA | data or information resource, database | Human genetics data from an immense (78,000) and ethnically diverse population available for secondary analysis to qualified researchers through the database of Genotypes and Phenotypes (dbGaP). It offers the opportunity to identify potential genetic risks and influences on a broad range of health conditions, particularly those related to aging. The GERA cohort is part of the Research Program on Genes, Environment, and Health (RPGEH), which includes more than 430,000 adult members of the Kaiser Permanente Northern California system. Data from this larger cohort include electronic medical records, behavioral and demographic information from surveys, and saliva samples from 200,000 participants obtained with informed consent for genomic and other analyses. The RPGEH database was made possible largely through early support from the Robert Wood Johnson Foundation to accelerate such health research. The genetic information in the GERA cohort translates into more than 55 billion bits of genetic data. Using newly developed techniques, the researchers conducted genome-wide scans to rapidly identify single nucleotide polymorphisms (SNPs) in the genomes of the people in the GERA cohort. These data will form the basis of genome-wide association studies (GWAS) that can look at hundreds of thousands to millions of SNPs at the same time. The RPGEH then combined the genetic data with information derived from Kaiser Permanente''s comprehensive longitudinal electronic medical records, as well as extensive survey data on participants'' health habits and backgrounds, providing researchers with an unparalleled research resource. As information is added to the Kaiser-UCSF database, the dbGaP database will also be updated. | genotype, phenotype, genome-wide association study, saliva, dna, male, female, health condition, electronic medical record, single nucleotide polymorphism, adult human, late adult human, gene, genome |
has parent organization: NCBI database of Genotypes and Phenotypes (dbGap) has parent organization: University of California at San Francisco; California; USA |
Aging, Cardiovascular disease, Osteoarthritis, Depressive Disorder, Insomnia, Eye disease, Cancer, Diabetes | NIMH ; NIH Office of the Director ; NIA AG036607 |
Application required, Non-commercial, Data Use Certification Agreement | nlx_157735 | SCR_010472 | Genetic Epidemiology Research on Aging | 2026-02-14 02:06:11 | 9 | |||||
|
Ontology of Geographical Region Resource Report Resource Website |
Ontology of Geographical Region (RRID:SCR_010398) | OGR | data or information resource, ontology, controlled vocabulary | Ontology that is used with other ontologies to represent the genetic susceptibility factors of diabetes. This OWL ontology classified the geograhical regions related vocabularies extracted from UMLS. | owl | is listed by: BioPortal | Diabetes | nlx_157530 | SCR_010398 | 2026-02-14 02:01:57 | 0 | ||||||||
|
Type 1 Diabetes - Rapid Access to Intervention Development Resource Report Resource Website |
Type 1 Diabetes - Rapid Access to Intervention Development (RRID:SCR_000203) | T1D-RAID | service resource, resource | NOTE: The T1D-RAID program is not currently accepting applications. Cooperative program that makes available, on a competitive basis, NCI resources for the pre-clinical development of drugs, natural products, and biologics to facilitate translation to the clinic of novel, scientifically meritorious therapeutic interventions for type 1 diabetes and its complications. A partial listing of those services includes: high-throughput screening, studies in animal models, formulation, pharmacology and toxicology studies, and bulk substances acquisition. Requests to T1D-RAID are brief (20 pages or less), and should clearly outline the resources required to ready the proposed therapeutic agent for clinical trials. T1D-RAID should enable entry into the clinic of promising molecules that are not otherwise likely to receive an adequate and timely clinical test. T1D-RAID is designed to accomplish the tasks that are rate-limiting in bringing discoveries from the laboratory to the clinic. Once a project has been approved, NIDDKstaff interact directly with the Principal Investigator (PI). NCI contractors perform the T1D-RAID-approved tasks under the direction of NIDDKand NCI staff. The required tasks will vary from project to project. In some cases T1D-RAID will support only one or two key missing steps necessary to bring a compound to the clinic; in other cases it may be necessary to supply the entire portfolio of development requirements needed to file an IND. Examples of tasks that can be supported by T1D-RAID include, but are not limited to: * Definition or optimization of dose and schedule for in vivo activity * Development of pharmacology assays * Conduct of pharmacology studies with a pre-determined assay * Acquisition of bulk substance (GMP and non-GMP) * Scale-up production from lab-scale to clinical-trials lot scale * Development of suitable formulations * Development of analytical methods for bulk substances * Production of dosage forms * Stability assurance of dosage forms * Range-finding initial toxicology * IND-directed toxicology, with correlative pharmacology and histopathology * Planning of clinical trials * Regulatory affairs, so that FDA requirements are likely to be satisfied by participating investigators seeking to test new molecular entities in the clinic * IND filing advice The output of T1D-RAID activities will be both products and information that will be made fully available to the originating investigator for support of an IND application and clinical trials. T1D-RAID does not sponsor clinical trials. | therapeutic, drug, drug development, pharmacogenomics |
is listed by: NIDDK Information Network (dkNET) is related to: Type 1 Diabetes Preclinical Testing Program has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Diabetes | NCI ; NIDDK |
nlx_152742 | SCR_000203 | Type 1 Diabetes - Rapid Access to Intervention Development (T1D-RAID) | 2026-02-14 02:07:45 | 0 | ||||||
|
National Diabetes Education Program Resource Report Resource Website 10+ mentions |
National Diabetes Education Program (RRID:SCR_001477) | NDEP | training resource, resource | Federal government public education program that promotes diabetes prevention and control. They aim to reduce the morbidity and mortality associated with diabetes and its complications. The NDEP is jointly sponsored by the National Institutes of Health and the Centers for Disease Control and Prevention and over 200 partner organizations. Target audiences include people with diabetes and those at risk, including the racial and ethnic populations disproportionately affected by the disease, health care providers and payers and purchasers of health care. | treatment, outcome, diabetes, diagnosis, prevention, blood glucose level, complication, education, disease-related portal |
is listed by: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Type 2 diabetes, Diabetes | NIDDK N02DK72927-8-0-1 | Free, Freely available | nlx_152708 | SCR_001477 | 2026-02-14 02:07:18 | 38 | ||||||
|
Diabetes Prevention Program Outcomes Study Resource Report Resource Website |
Diabetes Prevention Program Outcomes Study (RRID:SCR_001502) | DPPOS | data or information resource, clinical trial, database, resource | Observational clinical trial studying the long term effect of diet and exercise and the diabetes medication, metformin, on the delay of type 2 diabetes in participants of the Diabetes Prevention Program (DPP). The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%. The DPPOS is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest IGT population ever studied. Clinically important research questions remain that focus on 1)durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding CVD, CVD risk factors and atherosclerosis and microvascular disease, 3)close examination of these topics in men vs women and in minority populations. More than 87% of the original surviving DPP cohort has joined DPPOS as of December, 2007 and, to date, after 5 years of DPPOS and 10 years of combined DPP/DPPOS, 93% of the DPPOS cohort continue to attend annual follow-up visits. Interim analyses performed after 5 years of DPPOS have demonstrated a durable effect of diabetes prevention associated with the lifestyle and metformin interventions with 34 and 19% reductions in diabetes incidence, respectively, compared with the placebo group. Interim analyses also reveal significant reductions from baseline in CVD risk factors in the lifestyle intervention group, but with decreased utilization of glucose-lowering and lipid-lowering medications. Analyses of the participants in the placebo group who have developed diabetes during DPP/DPPOS, compared with those who have remained non-diabetic, reveal an increased frequency of retinopathy and microalbuminuria. The current, updated protocol describes the DPPOS including the revisions incorporated to complete the second five-years of the study. DPPOS participants have blood samples stored at the time of each annual visit. Specimens are stored at the study CBL until after the primary study outcomes are reported. DNA samples were previously collected and are stored at the NIDDKsample repository for DPP participants. | adult human, late adult human, male, female, caucasian, african-american, hispanic american, asian, pacific islander-american, american indian, metformin, microangiopathic, neuropathic, outcome, placebo, diabetic retinopathy, diabetic neuropathy, albuminuria, renal failure, macrovascular disease, cardiovascular disease, atherosclerosis, risk factor, amputation, hospitalization, physical activity, nutrition, body mass, obesity, dietary behavior, exercise behavior, physical functioning, quality of life, health care cost, cognitive performance, urinary incontinence, observational, microvascular disease, blood, dna |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Central Repository has parent organization: George Washington University; Washington D.C.; USA |
Type 2 diabetes, Diabetes | NIDDK U01DK048514; NIDDK U01DK048437; NIDDK U01DK048413; NIDDK U01DK048406; NIDDK U01DK048380; NIDDK U01DK048397 |
Free, Freely available | nlx_152800 | SCR_001502 | 2026-02-14 02:07:27 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
